Cowen reaffirmed their hold rating on shares of Amyris (NASDAQ:AMRS) in a report released on Wednesday morning. They currently have a $4.00 price objective on the biotechnology company’s stock.

AMRS has been the topic of several other reports. HC Wainwright set a $15.00 price objective on shares of Amyris and gave the stock a buy rating in a research report on Friday, August 11th. Zacks Investment Research upgraded shares of Amyris from a hold rating to a buy rating and set a $3.75 price objective on the stock in a research report on Wednesday, October 4th. Finally, ValuEngine upgraded shares of Amyris from a strong sell rating to a sell rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The company has an average rating of Hold and an average target price of $20.69.

Shares of Amyris (NASDAQ:AMRS) opened at $3.58 on Wednesday. Amyris has a 1 year low of $1.86 and a 1 year high of $13.05. The company has a current ratio of 0.92, a quick ratio of 0.82 and a debt-to-equity ratio of -0.78.

Amyris (NASDAQ:AMRS) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The company had revenue of $24.20 million for the quarter, compared to analyst estimates of $36.30 million. During the same quarter in the previous year, the company earned ($0.07) EPS. The firm’s quarterly revenue was down 8.8% on a year-over-year basis. sell-side analysts forecast that Amyris will post -3.32 EPS for the current year.

Hedge funds have recently made changes to their positions in the stock. Carl Domino Inc acquired a new position in Amyris in the 3rd quarter valued at about $182,000. Bank of New York Mellon Corp raised its stake in Amyris by 16.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 4,603 shares during the last quarter. Tanaka Capital Management Inc. raised its stake in Amyris by 72.0% in the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after purchasing an additional 221,295 shares during the last quarter. Finally, KBC Group NV raised its stake in Amyris by 228.4% in the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 41,834 shares during the last quarter. 26.06% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/amyris-amrs-hold-rating-reaffirmed-at-cowen/1741141.html.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.